OnKure Therapeutics, Inc. Class A (OKUR)

On October 7, 2024, OnKure Therapeutics completed its merger with Reneo Pharmaceuticals, Inc., and began trading on the Nasdaq Global Market under the ticker symbol "OKUR". This merger was accompanied by a $65 million private placement and a 1-for-10 reverse stock split by Reneo. The stock price has seen a substantial decline, with a 63.89% decrease from January 8, 2025, to January 7, 2026, and a 59.82% decrease over the last year. In December 2024, OnKure announced encouraging preliminary data from the PIKture-01 trial, showing OKI-219 was well tolerated. Analysts have initiated coverage with "Strong Buy" recommendations and an average price target of $32 as of August 26, 2025.

OnKure Therapeutics, Inc. does not experience traditional product demand seasonality, as its lead product candidate, OKI-219, is still in Phase 1 clinical trials. The demand for its products is currently in the form of investor interest and funding based on the progress of its clinical trials and development pipeline. There is some indication of stock performance seasonality, with October historically showing the highest probability of a positive return for OKUR stock (80%), while June has the lowest (20%).

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines for cancer, operating in the Healthcare sector, specifically in the Biotechnology and Pharmaceutical industry, with a focus on Drug Discovery. The company develops small molecule therapies using a structure and computational chemistry-driven drug design platform. Its lead product candidate, OKI-219, is in Phase 1 clinical trials for solid tumors, including breast cancer, and the company is also developing other programs targeting oncogenic mutations within the PI3K pathway.

OnKure Therapeutics, Inc. is headquartered in Boulder, Colorado, United States. The company also had an additional leased space in Irvine, California, which has been subleased following its merger with Reneo Pharmaceuticals, Inc.

OnKure Therapeutics' brand reputation has been positively influenced by the promising preliminary clinical results for its lead drug candidate, OKI-219. The initial phase of the PIKture-01 trial demonstrated a favorable safety and tolerability profile, with no reported dose interruptions, delays, or reductions, and only minor treatment-related adverse events.

OnKure Therapeutics, Inc. has significant institutional ownership, with 75.43% of its stock held by institutional shareholders. New Enterprise Associates 15 LP is the largest individual shareholder, owning 35.32% of the company's shares. Insiders hold 187.41% of the stock, while retail investors hold 0.00%.